The role of metformin and resveratrol in the prevention of hypoxia-inducible factor 1α accumulation and fibrosis in hypoxic adipose tissue

British Journal of Pharmacology

Volumn 173, Issue 12, 2016, Pages 2001-2015

  Li, Xiaole ^a   Li, Jia ^a   Wang, Lulu ^a   Li, Aiyun ^a   Qiu, Zhixia ^a   Qi, Lian Wen ^a   Kou, Junping ^a   Liu, Kang ^a   Liu, Baolin ^a   Huang, Fang ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; COLLAGEN TYPE 3; COLLAGEN TYPE 3ALPHA; COLLAGEN TYPE 6; COLLAGEN TYPE 6ALPHA; ELASTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 2ALPHA; INOSITOL REQUIRING ENZYME 1ALPHA; INTERLEUKIN 6; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN IRE1; PROTEIN LYSINE 6 OXIDASE; RESVERATROL; SIRTUIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; STILBENE DERIVATIVE;

3T3 CELL LINE; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENDOPLASMIC RETICULUM STRESS; FIBROSIS; GENE EXPRESSION; HYPOXIA; MALE; MOUSE; NONHUMAN; OXYGEN CONSUMPTION; OXYGEN TENSION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; 3T3-L1 CELL LINE; ANIMAL; CELL CULTURE; DOSE RESPONSE; DRUG EFFECTS; INFLAMMATION; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; PATHOLOGY; STRUCTURE ACTIVITY RELATION;

3T3-L1 CELLS; ADIPOSE TISSUE; ANIMALS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROSIS; HYPOXIA; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INFLAMMATION; MALE; METFORMIN; MICE; MICE, INBRED ICR; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84971216547     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13493     Document Type: Article

References (35)

1. Alexander SP, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE, et al., (2015a). The concise guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J Pharmacol 172: 5744-5869.
2. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, et al., (2015b). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024-6109.
3. Bai J, Zhang N, Hua Y, Wang B, Ling L, Ferro A, et al., (2013). Metformin inhibits angiotensin II-induced differentiation of cardiac fibroblasts into myofibroblasts. PLoS One 8: e72120.
4. Bai Y, Lu H, Wu C, Liang Y, Wang S, Lin C, et al., (2014). Resveratrol inhibits epithelial-mesenchymal transition and renal fibrosis by antagonizing the hedgehog signaling pathway. Biochem Pharmacol 92: 484-493.
5. Brasnyó P, Molnár GA, Mohás M, Markóal L, Laczyal B, Cseh J, et al., (2011). Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Brit J Nutr 106: 383-389.
6. Chen T, Li J, Liu J, Li N, Wang S, Liu H, et al., (2015). Activation of SIRT3 by resveratrol ameliorates cardiac fibrosis and improves cardiac function via TGF-β/Smad3 pathway. Am J Physiol-Heart C 308: H424-H434.
7. Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SPA, Giembycz MA, et al., (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461-3471.
8. Di Pascoli M, Diví M, Rodríguez-Vilarrupla A, Rosado E, Gracia-Sancho J, Vilaseca M, et al., (2013). Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats. J Hepatol 58: 904-910.
9. Emerling BM, Viollet B, Tormos KV, Chandel NS, (2007). Compound C inhibits hypoxic activation of HIF-1 independent of AMPK. FEBS Lett 581: 5727-5731.
10. + induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell 155: 1624-1638.
11. Halberg N, Khan T, Trujillo ME, Wernstedt-Asterholm I, Attie AD, Sherwani S, et al., (2009). Hypoxia-inducible factor 1α induces fibrosis and insulin resistance in white adipose tissue. Mol Cell Biol 29: 4467-4483.
12. Hattori Y, Suzuki K, Hattori S, Kasai K, (2006). Metformin inhibits cytokine-induced nuclear factor κB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension 47: 1183-1188.
13. Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K, et al., (2007). Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 56: 901-911.
14. Jiang C, Qu A, Matsubara T, Chanturyia T, Jou W, Gavrilova O, et al., (2011). Disruption of hypoxia-inducible factor 1 in adipocytes improves insulin sensitivity and decreases adiposity in high-fat diet-fed mice. Diabetes 60: 2484-2495.
15. Kagan HM, Li W, (2003). Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem 88: 660-672.
16. Khan T, Muise ES, Iyengar P, Wang ZV, Chandalia M, Abate N, et al., (2009). Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. Mol Cell Biol 29: 1575-1591.
17. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
18. Kim H, Moon SY, Kim JS, Baek CH, Kim M, Min JY, et al., (2015). Activation of AMP-activated protein kinase inhibits ER stress and renal fibrosis. Am J Physiol-Renal 308: F226-F236.
19. + system. Genes Dev 26: 259-270.
20. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, et al., (2006). Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell 127: 1109-1122.
21. Lee CG, Carr MC, Murdoch SJ, Mitchell E, Woods NF, Wener MH, et al., (2009). Adipokines, inflammation, and visceral adiposity across the menopausal transition: a prospective study. J Clin Endocrinol Metab 94: 1104-1110.
22. 2 consumption triggers HIF-1α, causing inflammation and insulin resistance in obesity. Cell 157: 1339-1352.
23. McGrath JC, Lilley E, (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol 172: 3189-3193.
24. Owen MR, Doran E, Halestrap AP, (2000). Evidence that metformin exerts its anti-diabetic effects through inhibition of complex I of the mitochondrial respiratory chain. Biochem J 348: 607-614.
25. Ozturk ZA, Kadayifci A, (2014). Insulin sensitizers for the treatment of non-alcoholic fatty liver disease. World J Hepatol 6: 199-206.
26. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al., (2014). The IUPHAR/BPS guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucleic Acids Res 42: D1098-D1106.
27. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, et al., (2008). NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 453: 807-811.
28. Ruderman NB, Xu XJ, Nelson L, Cacicedo JM, Saha AK, Lan F, et al., (2010). AMPK and SIRT1: a long-standing partnership? Am J Physiol-Endoc M 298: E751-E760.
29. Semenza GL, (2012). Hypoxia-inducible factors in physiology and medicine. Cell 148: 399-408.
30. Sun K, Halberg N, Khan M, Magalang UJ, Scherer PE, et al., (2013a). Selective inhibition of hypoxia-inducible factor 1α ameliorates adipose tissue dysfunction. Mol Cell Biol 33: 904-917.
31. Sun K, Tordjman J, Clément K, (2013b). Fibrosis and adipose tissue dysfunction. Cell Metab 18: 470-477.
32. Sun Y, Li J, Xiao N, Wang M, Kou J, Qi L, et al., (2014). Pharmacological activation of AMPK ameliorates perivascular adipose/endothelial dysfunction in a manner interdependent on AMPK and SIRT1. Pharmacol Res 89: 19-28.
33. Takiyama Y, Harumi T, Watanabe J, Fujita Y, Honjo J, Shimizu N, et al., (2011). Tubular injury in a rat model of type 2 diabetes is prevented by metformin: a possible role of HIF-1α expression and oxygen metabolism. Diabetes 60: 981-992.
34. Trayhurn P, (2013). Hypoxia and adipose tissue function and dysfunction in obesity. Physiol Rev 93: 1-21.
35. Xiao H, Ma X, Feng W, Fu Y, Lu Z, Xu M, et al., (2010). Metformin attenuates cardiac fibrosis by inhibiting the TGF β1-Smad3 signalling pathway. Cardiovasc Res 87: 504-513.